QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
IPO Year:
Exchange: NYSE
Website: qiagen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/24/2025 | $55.00 | Overweight | Barclays |
| 4/4/2025 | Buy → Neutral | Redburn Atlantic | |
| 2/19/2025 | $52.00 → $42.00 | Outperform → Neutral | Robert W. Baird |
| 1/6/2025 | $48.00 | Overweight → Equal-Weight | Morgan Stanley |
| 12/10/2024 | $42.50 → $54.00 | Hold → Buy | Jefferies |
| 10/17/2024 | $49.00 | Buy → Hold | HSBC Securities |
| 6/27/2024 | $50.00 | Peer Perform → Outperform | Wolfe Research |
| 12/19/2023 | $44.00 | Equal Weight | Wells Fargo |
| 12/13/2023 | Peer Perform | Wolfe Research | |
| 12/7/2023 | $50.00 | Neutral → Buy | Goldman |
Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NGS platforms such as PacBio for applications including structural variants, HLA typing and repeat expansions QIAGEN supporting fully integrated workflow from best-in-class sample preparation through to powerful bioinformatics for analysis and interpretation QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions. This new offering strengthens QIAGEN's position as a
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025. Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0402 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 1992038 To avoid waiting time, please join the event co
Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate G
GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay development GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic laboratories a range of clinical oncology assays QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics. GENCURIX is the first development partner under QI
QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) and Incyte (NASDAQ:INCY) today announced a ne
Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN's QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples. "Partnering with QIAGEN enables Tracer to bring our solid tumor MRD expertise to a broader market using a robust digital PCR platform i
Two new partnerships enhance QIAGEN's capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR Tracer Biotechnologies partnership to develop blood-based minimal residual disease (MRD) tests on QIAcuity digital PCR systems for solid cancer tumors Collaboration with Foresight Diagnostics aims to develop a kit version of its CLARITY™ NGS assay for use in lymphoma QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to suppo
BOULDER, Colo., Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) to develop and commercialize a kit-based version of Foresight's CLARITY™ assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies. This collaboration combines Foresight's innovative MRD detection technol
Partnership designed to expand QIAGEN's leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research Combines QIAGEN's global reach and automation expertise with ID Solutions' assay development for research purposes and manufacturing strengths QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications. The combination of QIAGEN's glob
Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide with easy-to-use, fast and flexible NGS data interpretation in a rapidly growing market Franklin complements QCI Interpret, QCI Precision Insights and QIAGEN's leading genetic databases COSMIC and HGMD QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin, Genoox's f
Barclays initiated coverage of Qiagen with a rating of Overweight and set a new price target of $55.00
Redburn Atlantic downgraded Qiagen from Buy to Neutral
Robert W. Baird downgraded Qiagen from Outperform to Neutral and set a new price target of $42.00 from $52.00 previously
Morgan Stanley downgraded Qiagen from Overweight to Equal-Weight and set a new price target of $48.00
Jefferies upgraded Qiagen from Hold to Buy and set a new price target of $54.00 from $42.50 previously
HSBC Securities downgraded Qiagen from Buy to Hold and set a new price target of $49.00
Wolfe Research upgraded Qiagen from Peer Perform to Outperform and set a new price target of $50.00
Wells Fargo initiated coverage of Qiagen with a rating of Equal Weight and set a new price target of $44.00
Wolfe Research initiated coverage of Qiagen with a rating of Peer Perform
Goldman upgraded Qiagen from Neutral to Buy and set a new price target of $50.00
6-K - QIAGEN N.V. (0001015820) (Filer)
SD - QIAGEN N.V. (0001015820) (Filer)
SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
6-K - QIAGEN N.V. (0001015820) (Filer)
SCHEDULE 13G - QIAGEN N.V. (0001015820) (Subject)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its
BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer
JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the Supervisory Board in 2020 to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Mr. Ebeling brings the number of current Supervisory Board members to eight. “On behalf of the Supervisory Board and Managing Board, I would like to welcome Th
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025. Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0402 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 1992038 To avoid waiting time, please join the event co
Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate G
Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 Net sales growth of +7% CER ahead of outlook for about +3% CER growth and adjusted diluted EPS of $0.56 CER ahead of outlook for at least $0.50 CER 29.8% adj. operating income margin up 4.1 percentage points vs. 25.7% in Q1 2024 Operating cash flow of $140 million in Q1 2025 vs. $133 million in Q1 2024 Proposal at Annual General Meeting to introduce a dividend as expansion of capital allocation strategy, also seek authorization for a new $500 million share repurchase Stephen H. Rusckowski proposed to become new Chairman
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Board's decision on the amended dividend policy and initial dividend payment is subject to approval by QIAGEN's shareholders. The initial dividend payment would consist of $0.25 per ordinary share. This proposal represents a total payout of a
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 5803222 To avoid waiting time, please join the event conference 5-10 minute
Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for at least $520 million CER and adjusted diluted EPS of $0.61 CER ahead of outlook for at least $0.60 CER QIAstat-Dx, QuantiFERON and QIAcuity digital PCR continue double-digit growth pace 30.6% adj. operating income margin up 2.6 percentage points vs. 28.0% in Q4 2023 FY 2024: Exceeded outlook for sales and adj. EPS; adj. operating income margin improves 1.8 percentage points to 28.7% Free cash flow rises 63% to $506 million 2025 outlook for about 4% CER sales grow
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 4027 GER: +49 (0)69 6610 2480 Conference ID: 9237018 To avoid waiting time, please join the event confer
Venlo, the Netherlands, Nov. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced results for the third quarter and first nine months of 2024. Net sales rose 5% to $502 million in Q3 2024 over Q3 2023, while results at constant exchanges rates (CER) of $502 million rose 6% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose three percentage points to 29.6% on benefits from the recent decision to discontinue the NeuMoDx system as well as broader efficiency gains that have improved profitability and freed up resources for targeted reinvestment. Adjusted diluted earnings per share (EPS) were $0
Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024. Press release date / time: Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0448UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID:
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
SC 13G - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)